## Please fax both pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form Oncology REMS



## Four simple steps to submit your referral.

1 Patient Information	on	/ 10=11	opies of front and back of all medical insurance cards.
New patient			
			Middle initial
			Date of birth
			Apt #
			Zip
			S
- ' '			_
			S
			•
OK to leave message with alternate	·	Email address	S
-	_	nasa specify	
ratient's primary language: Englisi	i Other if other, pie	ease specify	
2 Prescriber Inform	ation	All fields must be complete	ed to expedite prescription fulfillment.
Date Ti	me	Date medication needed	
Office/clinic/institution name			
Prescriber's first name		Last name	
Prescriber's title		If NP or PA, under direction of D	r
Office phone	Fax	NPI #	License #
Office contact and title		Office contact email	
			Suite #
			 Zip
Deliver product to: Prescriber's office			
rescriber 3 office	ce Tatient's nome		
2 00 00 00 00 00 00			
3 Clinical Information	on		
Primary ICD-10 code (REQUIRED):			
Current weight kg/l	bs Height	inches/cm	
BSA	m <sup>2</sup> Date ol	btained	
Patient type from PPAF (check one):	Adult Male Male Cl	hild Adult Female – NOT of Reproc	luctive Potential
• •			

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

L
Г

## **Prescribing Information**

Medication	Strength/ Formulation	Directions	Quantity/Refills
Pomalyst® 1mg capsule (pomalidomide) 2mg capsule 3mg capsule 4mg capsule	2mg capsule	Takecapsule(s) daily Takecapsule(s) fordays on anddays off	Quantity
	For Multiple Myeloma: The recommended starting dose of Pomalyst is 4mg/day orally for Days 1 – 21 of repeated 28-day cycles. Pomalyst should be given in combination with dexamethasone. Dosing is continued or modified based upon clinical and laboratory findings.  Authorization # Date (To be filled in by healthcare provider)  Patient type from PPAF (check one): Adult Male Male Child  Adult Female – NOT of Reproductive Potential Adult Female – Reproductive Potential Female Child – NOT of Reproductive Potential Female Child – Reproductive Potential	No refills	
Revlimid® (lenalidomide)  2.5mg capsule 5mg capsule 10mg capsule 20mg capsule 20mg capsule 25mg capsule	Takecapsule(s) daily Takecapsule(s) fordays on anddays off	Quantity No refills	
	Myelodysplastic Syndromes and Multiple Myeloma maintenance following autologous hematopoietic stem cell transplantation: The recommended starting dose of Revlimid is 10mg/day with water. Dosing is continued or modified based upon clinical and laboratory findings.  Multiple Myeloma and Mantle Cell Lymphoma: The recommended starting dose of Revlimid is 25mg/day orally for Days 1 – 21 of repeated 28-day cycles. Dosing is continued or modified based upon clinical and laboratory findings.		
	Authorization # Date (To be filled in by healthcare provider)  Patient type from PPAF (check one): Adult Male Male Child  Adult Female – NOT of Reproductive Potential Adult Female – Reproductive  Potential Female Child – NOT of Reproductive Potential  Female Child – Reproductive Potential		
Thalomid® (thalidomide) 50mg capsule 100mg capsule 150mg capsule 200mg capsule	Takecapsule(s) daily Takecapsule(s) fordays on anddays off	Quantity  No refills	
		Multiple Myeloma: The recommended starting dose of Thalomid is 200mg/day orally with water for a 28-day treatment cycle. Dosing is continued or modified based upon clinical and laboratory findings.  Erythema Nodosum Leprosum: The recommended starting dose of Thalomid is 100 to	No Terms
		300mg/day with water for an episode of cutaneous ENL. Up to 400mg/day for severe cutaneous ENL. Dosing is continued or modified based upon clinical and laboratory findings.	
		Authorization # Date (To be filled in by healthcare provider)  Patient type from PPAF (check one): Adult Male Male Child  Adult Female – NOT of Reproductive Potential Adult Female – Reproductive  Potential Female Child – NOT of Reproductive Potential  Female Child – Reproductive Potential	
Other			

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN	
HERE	

Date Dispense as written Date Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

